ArticleReproductive sciences (Thousand Oaks, Calif.)2026
Effect of Rho Kinase Inhibitor (Y27632) on Spermatogenesis in Azoospermic Mice Model.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in cancer therapy have markedly improved patient survival, thereby increasing the need for effective fertility preservation strategies. Chemotherapeutic agents commonly induce apoptosis in rapidly proliferating cells, including spermatogonia, resulting in long-term testicular damage. Y-27632, a Rho-associated coiled-coil-containing protein kinase (ROCK) inhibitor, has been shown to suppress apoptosis in various stem cell populations by modulating Rho GTPase-dependent signaling pathways. This study aimed to evaluate the protective effects of Y-27632 against busulfan-induced testicular injury in a murine model. Eighteen 4-week-old male C57BL/6 mice were randomly assigned to three groups: control (no treatment), busulfan (40 mg/kg), and busulfan plus Y-27632 (40 mg/kg busulfan + 5 mg/kg Y-27632). Seventy days after treatment, sperm parameters (count, motility, viability, and plasma membrane integrity) and testicular outcomes, including seminiferous tubule diameter, germinal epithelium thickness, tubular differentiation index, spermatogenesis index, Johnsen score, apoptotic gene expression, malondialdehyde levels, total antioxidant capacity, and TUNEL-positive cells, were assessed. Y-27632 administration significantly improved seminiferous tubule diameter and germinal epithelium thickness and increased tubular differentiation and spermatogenesis indices and Johnsen scores compared with the busulfan group. In addition, Y-27632 treatment was associated with reduced ERK gene expression and a lower number of TUNEL-positive cells. However, sperm parameters and testicular weight remained significantly reduced compared with controls, and no significant differences were observed in lipid peroxidation, total antioxidant capacity, or sperm DNA integrity among groups. In conclusion, Y-27632 partially attenuated busulfan-induced testicular damage by improving histological indices of spermatogenesis and reducing apoptosis, suggesting that ROCK inhibition may represent a potential adjunct strategy for fertility preservation following gonadotoxic cancer therapies.
Indexed as
Identifiers
42920066What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.